Al B. Benson III, MD, FACP, FACCC, FASCO
Articles
Clinical Considerations for 2L Treatment Sequencing in mCRC
John Marshall, MD;Al B. Benson III, MD, FACP, FACCC, FASCO ;Kristen Ciombor, MD, MSCI;Stacey A. Cohen, MD;Marwan Fakih, MD
June 26th 2024Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.
Read More
Overview of Molecular Testing and Barriers in mCRC
John Marshall, MD;Al B. Benson III, MD, FACP, FACCC, FASCO ;Kristen Ciombor, MD, MSCI;Stacey A. Cohen, MD;Marwan Fakih, MD
June 26th 2024The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.
Read More
Latest Updated Articles
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: June 4th 2024 | Updated: July 3rd 2024
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
Published: June 28th 2024 | Updated: July 3rd 2024
Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer
Published: June 4th 2024 | Updated: July 3rd 2024
Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma
Published: July 1st 2024 | Updated: July 3rd 2024
TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers
Published: June 22nd 2024 | Updated: July 3rd 2024
Garon Discusses the Standing and Future of ADCs, Targeted Therapies in NSCLC
